The Role of MRI and PET/SPECT in Alzheimers Disease
The DOI matches its Crossref record.
Abstract
Alzheimer's disease (AD) is difficult to diagnose in its early stages, and even if detected early, there is no preventative treatment. Imaging modalities such as MRI, PET, and SPECT have the potential to contribute to both the diagnosis of Alzheimer's disease, as well as assist in the search for more effective treatments. A number of AD-related biomarkers have been proposed and evaluated. The use of PET imaging to detect alterations in regional brain metabolism using [(18)F]FDG has enabled more sensitive and accurate early diagnosis of AD, especially in conjunction with traditional medical evaluation. Additionally, magnetic resonance imaging and spectroscopy provide a wide range of biomarkers that have been shown to correlate with the progression of AD. Some of these markers have been pursued in clinical trials. Progress has been made toward the evaluation of other more AD-specific biomarkers. However, many questions remain concerning the validity and sensitivity of these imaging biomarkers to aid in the assessment of potential new treatments, especially those related to increased levels of amyloid peptides in the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
A review of β-amyloid neuroimaging in Alzheimer's disease
Adlard, P. A., Tran, B. A., Finkelstein, D. I., Desmond, P. M., Johnston, L. A., Bush, A. I., & Egan, G. F. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00327 · Cited by 93
“While brain atrophy is not specific to AD, studies have revealed atrophy of the MTL is well correlated with changes in cognition and disease progression (Coimbra et al., 2006; Frisoni et al., 2010; Vemuri and Jack, 2010).”
BackgroundMethodResultInfluentialIn vivo diffusion tensor imaging of amyloid‐β‐induced white matter damage in mice
Sun, S.-W., Liang, H.-F., Mei, J., Xu, D., & Shi, W.-X. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130236 · Cited by 27
“turbances are a common complaint in AD [54–57],”
Metadata
- Authors
- Coimbra, A., Williams, D., & Hostetler, E.
- Venue
- Current Topics in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-03-01
- Volume
- 6
- Issue
- 6
- Pages
- 629-647
- ISSN
- 1568-0266 (ISSN-L)
- OpenAlex
- W2027751645
- Cited by
- 43
- References
- 0
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of MRI and PET/SPECT in Alzheimers Disease. https://app.cochat.ai/papers/10.2174/156802606776743075
- The paper
- Coimbra, A., Williams, D., & Hostetler, E. (2006). The Role of MRI and PET/SPECT in Alzheimers Disease. Current Topics in Medicinal Chemistry. https://doi.org/10.2174/156802606776743075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.